CTRI Number |
CTRI/2021/11/038131 [Registered on: 18/11/2021] Trial Registered Prospectively |
Last Modified On: |
11/01/2022 |
Post Graduate Thesis |
No |
Type of Trial |
Observational |
Type of Study
|
Cohort Study |
Study Design |
Single Arm Study |
Public Title of Study
|
Development of artificial intelligence based model to predict mortality in patients with acute-on-chronic liver failure |
Scientific Title of Study
|
Development, validation and deployment of a novel prediction model utilizing artificial intelligence on clinical and proteomic features to predict mortality among patients with acute-on-chronic liver failure |
Trial Acronym |
|
Secondary IDs if Any
|
Secondary ID |
Identifier |
NIL |
NIL |
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
Name |
Dr Nipun Verma |
Designation |
Assistant Professor |
Affiliation |
PGIMER, Chandigarh |
Address |
Department of Hepatology, Nehru Hospital Extension Block, PGIMER, Sector-12
Chandigarh CHANDIGARH 160012 India |
Phone |
9914208562 |
Fax |
|
Email |
nipun29j@gmail.com |
|
Details of Contact Person Scientific Query
|
Name |
Dr Nipun Verma |
Designation |
Assistant Professor |
Affiliation |
PGIMER, Chandigarh |
Address |
Department of Hepatology, Nehru Hospital Extension Block, PGIMER, Sector-12
CHANDIGARH 160012 India |
Phone |
9914208562 |
Fax |
|
Email |
nipun29j@gmail.com |
|
Details of Contact Person Public Query
|
Name |
Dr Nipun Verma |
Designation |
Assistant Professor |
Affiliation |
PGIMER, Chandigarh |
Address |
Department of Hepatology, Nehru Hospital Extension Block, PGIMER, Sector-12
CHANDIGARH 160012 India |
Phone |
9914208562 |
Fax |
|
Email |
nipun29j@gmail.com |
|
Source of Monetary or Material Support
|
IHUB Anubhuti IITD Foundation (TIH), New Delhi, India |
|
Primary Sponsor
|
Name |
IHUB Anubhuti IITD Foundation TIH |
Address |
Indraprastha Institute of Information Technology Delhi, Okhla Industrial Estate, Phase-III, New Delhi-110020 |
Type of Sponsor |
Other [Non-Profit Company] |
|
Details of Secondary Sponsor
|
|
Countries of Recruitment
|
India |
Sites of Study
|
No of Sites = 1 |
Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
Dr Nipun Verma |
Post Graduate Institute of Medical Education and Research, Chandigarh |
Department of Hepatology, Nehru Hospital Extension Block, PGIMER, Sector-12 Chandigarh CHANDIGARH |
9914208562
nipun29j@gmail.com |
|
Details of Ethics Committee
|
No of Ethics Committees= 1 |
Name of Committee |
Approval Status |
Institute Ethics committee, PGIMER |
Approved |
|
Regulatory Clearance Status from DCGI
|
|
Health Condition / Problems Studied
|
Health Type |
Condition |
Patients |
(1) ICD-10 Condition: K74||Fibrosis and cirrhosis of liver, |
|
Intervention / Comparator Agent
|
|
Inclusion Criteria
|
Age From |
18.00 Year(s) |
Age To |
80.00 Year(s) |
Gender |
Both |
Details |
Patients with a confirmed diagnosis of ACLF either by EASL criteria or by APASL criteria |
|
ExclusionCriteria |
Details |
Patients with HIV infection, pregnant or lactating women, patients having any active malignancy or previous organ-transplantation and those refusing to give a consent will be excluded |
|
Method of Generating Random Sequence
|
Not Applicable |
Method of Concealment
|
Not Applicable |
Blinding/Masking
|
Not Applicable |
Primary Outcome
|
Outcome |
TimePoints |
Derivation of AI/ML model for prediction of mortality in ACLF patients |
After establishment of clinical and proteomic database, model derivation phase will began in first one and a half year |
|
Secondary Outcome
|
Outcome |
TimePoints |
Development of web application for AI model deployment |
After internal validation of model, a validation cohort will be recruited and for model validation and refinement in next one and a half year |
|
Target Sample Size
|
Total Sample Size="200" Sample Size from India="200"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
Phase of Trial
|
N/A |
Date of First Enrollment (India)
|
24/11/2021 |
Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
Date of First Enrollment (Global) |
Date Missing |
Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
Estimated Duration of Trial
|
Years="3" Months="0" Days="0" |
Recruitment Status of Trial (Global)
Modification(s)
|
Open to Recruitment |
Recruitment Status of Trial (India) |
Open to Recruitment |
Publication Details
|
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
Brief Summary
|
Liver cirrhosis is the most common cause of
death among gastrointestinal diseases, with a global burden of 1.5 billion
persons being affected annually. It is the 4th and 10th
most common cause of disease in males and females, respectively.
Acute-on-chronic liver failure (ACLF) development is the most common cause of
death in these patients. The mortality of this dynamic syndrome ranges from
15-100% within 30-days and 90-100% within one year of presentation. Multiple
life-threatening events like sepsis, organ failures, and gastrointestinal
bleeding may occur during its course. This proposal is aimed to develop,
validate, and deploy a novel model to predict mortality among patients with
acute-on-chronic liver failure (ACLF). The model will be derived from clinical,
biochemical, radiological and plasma proteomics data obtained from patients
with ACLF. Principles of AI, machine learning, and bioinformatics will be
utilized to build such a model. The model aims to incorporate the systems
approach to medicine with clinical sciences and information technology sector.
The proposal includes multiple innovations. It will develop a multimedia
processing engine (converting the existing data in a ready format for ML and AI
modeling), development, and deployment of AI-derived model for real-time
predictive analytics. The models’ deployment will contribute to the development
of user-friendly data analytic apps. The models may be used to assess the
futility of care and allocate significant resources like ICU and mechanical
ventilators to deserving patients. Importantly, patients’ lives can be saved
with a timely decision for definitive treatment (liver transplant) using these
models.
This
proposal aligns with the mandate of TiH in terms of knowledge generation
(development of clinical and proteomic database), technology product
development (portable AI model), skill development (integration of skills such
as clinical, biochemical, bioinformatics and information technology),
collaboration (between clinicians, basic scientist, computational biologist,
and information technologist). |